Watch demo video below.
Skope, Inc. is a privately held medical technology company focused on combatting hospital acquired infections through stethoscope disinfection.
Stethoscopes are the most used medical device, yet the vast majority are contaminated with dangerous organisms. They have been documented to spread disease, and all major healthcare agencies (including the CDC) recommend that stethoscopes be disinfected after every use. Current methods of stethoscope disinfection are ineffective, expensive, and highly inconvenient for caregivers.
“I like the convenience of the Skope Station – it is so simple and easy to use.”Cardiology RN
The Skope Station is a point-of-care, wall-mounted device which uses a disposable internal cartridge containing an EPA-approved disinfectant to eradicate all infectious organisms (including viruses such as Covid-19, bacterial spores and MRSA) on a stethoscope’s diaphragm. It does this quickly and economically, with only a single swipe, thereby avoiding disruption of caregiver workflow. Microbiologic testing of the Skope Station prototype has been successfully conducted, and focus group feedback from doctors, nurses, and patients has been overwhelmingly positive.
The Skope Station disinfects all sizes and styles of stethoscopes – pediatric to adult, and acoustic to electronic.
“I can’t think why any patient would not like this product. It’s almost a little marketing tool for our MRSA department. It shows that we’re interested in cleanliness and non-transmission.”ED Physician
Skope’s executive team and board of directors are proven veterans with experience in medical device development and commercialization, IPO’s, acquisitions and private and institutional fundraising.
“I wish I had invented it.”Cardiac Rehab RN
Medical device executive and serial entrepreneur. David has held numerous leadership roles at Procter & Gamble, Boston Scientific, Covidien, Medtronic as well as many early/mid-stage medical device companies. He has launched technologies in over 13 specialties and serves on the board of several medical device companies and as an advisor at several universities.
Daniel Stromberg, MD
Practicing pediatric cardiologist and current Director of Cardiac Intensive Care at Dell Children’s Medical Center in Austin, Texas. He has over 20 years of clinical and research experience, as well as start-up experience.
Keith Rubin, MD
Internist and serial entrepreneur in the biotechnology space for the last 15 years; CEO of Seedlings Life Science Ventures; currently CEO of Iliad Biotechnologies; early developer of Skope technology.
Experienced developer of medical devices (>20 years) with expertise in regulatory compliance, design control and pilot manufacturing; has led teams at major med-tech companies (Bard, J&J Cordis); currently COO of Iliad Biotechnologies.
Currently Managing Director at Springbok Ventures, Rob is an entrepreneurial business executive (>25 years) across a number of sectors, including life sciences, software and healthcare IT. Led Savara, Inc. as CEO, and was the Life Sciences winner of the Ernst & Young Entrepreneur of the Year award in 2018.
Clay has more than 20 years of entrepreneurial and investor experience, having co-founded Evity, Inc. which sold to BMC Software. He has been involved in numerous early-stage ventures as an investor and founder, and currently serves as Managing Director at Springbok Ventures.
Large market opportunity
The Skope Station can be deployed to improve stethoscope hygiene in all clinical settings where the instrument is used: hospital ICUs, neonatal ICUs, ERs, and inpatient wards, plus outpatient clinics, long-term care facilities, and emergency vehicles. The Skope Station will replace ineffective and inconvenient stethoscope hygiene products within existing institutional stethoscope disinfection budgets.
Regulatory status and Intellectual Property
The Skope Station is an FDA Class 1 device and is exempt from 510K premarket notification. Skope has 10 issued US patents (3 design, 7 utility), and 10 patents issued in the UK and EU countries.
Skope’s early (and timely) entry into the stethoscope hygiene market, along with its convenient design, coverage within existing hospital budgets, IP protection, and low regulatory barrier will allow for widespread device adoption, and creation of a de facto standard in infection control. In so doing, the Skope Station will help address the costly and tragic problem of hospital acquired infections.
Please click the link below to see a list of publications on the topic of stethoscope hygiene.
Please fill out the contact form for more information about Skope Inc. or to learn about investment opportunities.
© 2023 Skope Inc. All Rights Reserved.